Study #2022-1085
A Phase 1, multicenter, open-label, first-in-human study of YL202 in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
YL202
Description
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non Small Cell Lung Cancer, Breast Cancer
Study phase:
Phase I
Physician name:
Senthil Damodaran
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.